ReviewNature reviews. Immunology2005
Immune responses to tuberculosis in developing countries: implications for new vaccines.
Review in Nature reviews. Immunology, 2005. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 52 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
52 citing papers in PubMed.
- A randomized, controlled dose-finding Phase II study of the M72/AS01 candidate tuberculosis vaccine in healthy PPD-positive adults.Journal of clinical immunology · 2013Trial
- Tuberculosis in patients with systemic lupus erythematosus.Frontiers in immunology · 2025Review
- Saponin TQL1055 adjuvant-containing vaccine confers protection uponHuman vaccines & immunotherapeutics · 2024Article
- The SH3-binding domain of chorismate mutase protein ofiScience · 2024Article
- The BCG vaccine, advantages, and disadvantages of introducing new generation vaccines againstClinical and experimental vaccine research · 2024Review
- Immunologic and imaging signatures in post tuberculosis lung disease.Tuberculosis (Edinburgh, Scotland) · 2022Review
- Emerging advances in identifying signal transmission molecules involved in the interaction betweenFrontiers in cellular and infection microbiology · 2022Review
- Effect of Helicobacter pylori and Helminth Coinfection on the Immune Response to Mycobacterium tuberculosis.Current microbiology · 2021Review
- Mucosal-Associated Invariant T Cells Develop an Innate-Like Transcriptomic Program in Anti-mycobacterial Responses.Frontiers in immunology · 2020Article
- Increased T Cell Differentiation and Cytolytic Function in Bangladeshi Compared to American Children.Frontiers in immunology · 2019Article
- Significance of the Differential Peptidome in Multidrug-Resistant Tuberculosis.BioMed research international · 2019Article
- CCR4-dependent reduction in the number and suppressor function of CD4Cell death & disease · 2018Article
- Article
- The Effect of Deworming on Tests of Tuberculosis Infection in Children With Recent Tuberculosis Exposure: A Randomized Controlled Trial.The Pediatric infectious disease journal · 2016Article
- Immune requirements for protective Th17 recall responses to Mycobacterium tuberculosis challenge.Mucosal immunology · 2015Article
- Prime-boost vaccination strategy with bacillus Calmette-Guérin (BCG) and liposomized alpha-crystalline protein 1 reinvigorates BCG potency.Clinical and experimental immunology · 2015Article
- Gene expression and cytokine profile correlate with mycobacterial growth in a human BCG challenge model.The Journal of infectious diseases · 2015Article
- Effectiveness of the First Dose of BCG against Tuberculosis among HIV-Infected, Predominantly Immunodeficient Children.BioMed research international · 2015Article
- Interaction of Pattern Recognition Receptors with Mycobacterium Tuberculosis.Journal of clinical immunology · 2015Review
- Small molecule-directed immunotherapy against recurrent infection by Mycobacterium tuberculosis.The Journal of biological chemistry · 2014Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Tuberculosis is out of control in developing countries, where it is killing millions of people every year. In these areas, the present vaccine - Mycobacterium bovis bacillus Calmette-Guérin (BCG) - is failing. Progressive tuberculosis occurs because the potentially protective T helper 1 (T(H)1)-cell response is converted to an immunopathological response that fails to eliminate the bacteria. Here, we discuss the data indicating that the problem in developing countries is not a lack of adequate T(H)1-cell responses but, instead, an exaggerated tendency to switch to immunopathological responses. We propose that a successful vaccine needs to block this immunopathology, because it is not the quantity of T(H)1-cell activity that matters but, rather, its context.
Indexed as
Identifiers
16056257What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.